THE FASTER WE MOVE

We're presenting at ASCO GU 2022!

We are absolutely thrilled that MEDSIR is attending the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium again this year. The 2022 ASCO GU Symposium will provide experts with an in-depth multidisciplinary perspective on the latest clinical and scientific advances in the diagnosis and treatment of genitourinary malignancies. An array of multidisciplinary sessions covering prostate, renal, penile, testicular, urothelial, and adrenal are to be featured.



The 2022 ASCO GU Symposium will be held from February 17 to 19, 2022 both, on-site in San Francisco and remotely online. More than 4,500 experts are expected to be in attendance.


Although breast cancer treatment remains the main driving force of MEDSIR, we are positioning ourselves to expand in the management of other oncologic malignancies, like genitourinary-related cancers. Therefore, while the goal of attending ASCO GU last few years was to become better acquainted with the field of genitourinary malignancies, this year we will be sharing our exciting clinical trials. MEDSIR will present the trial designs of ZZFIRST for management of patients with metastatic hormone-naïve prostate cancer (mHNPC) and ORPHEUS, aiming to help patients with penile squamous cell carcinoma (PSqCC).


ZZFIRST is a multi-center, open-label, randomized, two-arm, phase II clinical trial, focused on exploring the possibility to expand the population benefiting from PARP inhibition beyond mHNPC patients with homologous recombination alterations, and prolong the clinical benefit from patients receiving enzalutamide. This trial is evaluating the anti-tumor activity and safety of talazoparib in combination with enzalutamide and hormone therapy in patients with mHNPC. This poster will be presented virtually by Dr. Joaquin Mateo.


· Abstract Number: TPS209

· Abstract Title: A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.

· Session Information: Trials in Progress Poster Session A: Prostate Cancer, 2/17/2022, 11:30 AM-1:00 PM; 5:45 PM-6:45 PM.


Squamous cell carcinoma is the most common primary neoplasm of the penis. Today, patients with advanced PSqCC are a population with a poor prognosis, very limited treatment options, and a survival rate lower than one year. Our ORPHEUS study was designed to explore the clinical benefit of retifanlimab (also known as INCMGA00012), a humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, in patients with advanced PSqCC. This trial is evaluating the activity and tolerability of immunotherapy in a series of patients with advanced PSqCC regardless of their prior treatment, including patients with well-controlled HIV infection. This poster will be presented virtually by Dr. Xavier García del Muro.


· Abstract Number: TPS8

· Abstract Title: A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS.

· Session Information: Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers, 2/19/2022, 7:00 AM-8:00 AM; 12:45 PM-1:30 PM.


If you are a clinician, researcher or company in the GU domain and are looking for guidance for developing your research ideas, don’t miss out on the chance to meet with MEDSIR at ASCO GU. Contact us to connect! Likewise, if you are a patient attending the conference and would like to get in touch, please do so or check out our patient portal – All of what we do, we do for you!

GET OUR MONTHLY NEWSLETTER!